Overview

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Status:
Completed
Trial end date:
2019-04-26
Target enrollment:
Participant gender:
Summary
To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
Phase:
Phase 1
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
Acerta Pharma, LLC
Treatments:
Acalabrutinib
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate